Neurogene (NGNE) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Company overview and lead program

• Focuses on genetic medicines for rare neurologic diseases using a biology-first approach.

• Lead program NGN-401 targets Rett syndrome, a multi-billion dollar market with 15,000–20,000 patients in the US and Europe.

• NGN-401 pivotal study began dosing in Q4 2025, with enrollment and dosing completion expected in Q2 2026.

• Phase I/II data showed 35 milestones gained across 8 participants, indicating multi-domain, durable improvements.

• Upcoming catalyst is the completion of enrollment and 12-month data readout for all 10 patients in mid-2026.

Differentiation and technology

• NGN-401 uses a full-length human MECP2 gene and proprietary technology to regulate expression, minimizing toxicity.

• Delivery method ensures drug reaches neurons in the brain, addressing the root cause of Rett syndrome.

• Route of administration (ICV) is supported by caregivers, KOLs, and payers, who prioritize efficacy over delivery concerns.

• Payers focus on clear, objective efficacy endpoints, such as milestone gains.

Safety, dosing, and monitoring

• Previous HLH event at higher dose (3E15); current pivotal dose (1E15) is three times lower and has shown no HLH cases.

• Monitoring protocol includes ferritin and other immune markers for early detection and reversibility of adverse events.

• Nerve conduction issues observed were transient and align with known AAV gene therapy class effects.

• Safety updates will be disclosed if material events occur; current data shows no new safety concerns.